Epizyme (NASDAQ:EPZM) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.
Several other equities research analysts have also recently issued reports on EPZM. Zacks Investment Research cut Epizyme from a “buy” rating to a “hold” rating in a research note on Friday, December 7th. ValuEngine upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, December 15th. Finally, Wedbush restated an “outperform” rating and set a $21.00 target price on shares of Epizyme in a research note on Monday, November 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $19.44.
Shares of EPZM stock opened at $11.72 on Friday. The company has a market capitalization of $944.50 million, a P/E ratio of -5.38 and a beta of 3.00. Epizyme has a 1 year low of $5.14 and a 1 year high of $21.40.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Featured Article: What is a Swap?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.